Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019043127) A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/043127 International Application No.: PCT/EP2018/073404
Publication Date: 07.03.2019 International Filing Date: 30.08.2018
IPC:
C07K 14/005 (2006.01) ,C07K 14/47 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
01
DNA viruses
03
Herpetoviridae, e.g. pseudorabies virus
05
Epstein-Barr virus
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
Applicants:
INPROTHER APS [DK/DK]; Tolstojs Alle 14 2860 Soeborg, DK
Inventors:
HOLST, Peter; DK
THIRION, Christian; DE
NEUKIRCH, Lasse; DE
Agent:
BIRD & BIRD LLP; Michael Alt Maximiliansplatz 22 80333 München, DE
Priority Data:
PA 2017 7065901.09.2017DK
Title (EN) A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
(FR) VACCIN À UTILISER DANS LA PROPHYLAXIE ET/OU LE TRAITEMENT D'UNE MALADIE
Abstract:
(EN) The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
(FR) La présente invention concerne un vecteur adénoviral capable de coder une particule de type virus (VLP), cette VLP affichant un domaine immunosuppresseur (ISD) inactif. Le vaccin de l'invention présente une réponse immunitaire améliorée à partir de l'une ou l'autre des voies de réponse déclenchées par des lymphocytes T CD4 ou des lymphocytes T CD8.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)